Otonomy and Ipsen in licensing agreement on gacyclidine for OTO-311 in tinnitus

Ear disease and disorder specialist Otonomy (Nasdaq: OTIC) and French drugmaker Ipsen (Euronext: IPN) have entered into a licensing agreement which will enable Otonomy to use Ipsen’s gacyclidine data in the development and registration of OTO-311.

OTO-311 is Otonomy’s sustained-exposure formulation of gacyclidine, an N-Methyl-D-Aspartate receptor antagonist, which is being developed to treat tinnitus.

David Weber, president and chief executive of Otonomy, said: “We are pleased to complete this agreement with Ipsen which supports our plan to initiate OTO-311 clinical trials next year. Additionally, we believe that the clinical data set generated by Ipsen provides important insights into gacyclidine’s systemic profile that will inform our development of locally administered OTO-311 for the treatment of tinnitus.”